Literature DB >> 15507871

Nucleic acid aptamers in human viral disease.

Zhiren Zhang1, Michael Blank, Hermann J Schluesener.   

Abstract

Nucleic acid aptamers are short, single-stranded oligonucleotides or their modified analogues which avidly and specifically interact with targeted ligands through their 3-dimensional structure. Aptamers can be selected out of a large combinatorial oligonucleotide library through an in vitro evolution process termed SELEX. Since 1990, a wide variety of aptamers targeted to ligands ranging from small molecules to complex mixtures have been isolated. Most selected aptamers have shown high specificity to and affinity for their ligands and are potential detection and/or diagnostic reagents. Furthermore, some aptamers specifically inhibit biological functions of targeted proteins, resulting in potent therapeutic candidates in disease models. Some recent advances to increase the stability of aptamers, extend their in vivo circulation time and their in vivo expression have pushed aptamers closer to therapeutic applications. This review presents recent developments in the field of aptamer research and focuses on their applications to human viral diseases, particularly HIV induced diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507871

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  10 in total

1.  Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase.

Authors:  Jeffrey J DeStefano; Gauri R Nair
Journal:  Oligonucleotides       Date:  2008-06

2.  Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.

Authors:  Jiehua Zhou; Sangeetha Satheesan; Haitang Li; Marc S Weinberg; Kevin V Morris; John C Burnett; John J Rossi
Journal:  Chem Biol       Date:  2015-03-05

3.  A primer-free method that selects high-affinity single-stranded DNA aptamers using thermostable RNA ligase.

Authors:  Yi-Tak Lai; Jeffrey J DeStefano
Journal:  Anal Biochem       Date:  2011-03-21       Impact factor: 3.365

4.  DNA aptamers to human immunodeficiency virus reverse transcriptase selected by a primer-free SELEX method: characterization and comparison with other aptamers.

Authors:  Yi-Tak Lai; Jeffrey J DeStefano
Journal:  Nucleic Acid Ther       Date:  2012-05-03       Impact factor: 5.486

Review 5.  Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1.

Authors:  Jiehua Zhou; John J Rossi
Journal:  BioDrugs       Date:  2012-12-01       Impact factor: 5.807

6.  Selection of 2'-deoxy-2'-fluoroarabinonucleotide (FANA) aptamers that bind HIV-1 reverse transcriptase with picomolar affinity.

Authors:  Irani Alves Ferreira-Bravo; Christopher Cozens; Philipp Holliger; Jeffrey J DeStefano
Journal:  Nucleic Acids Res       Date:  2015-10-17       Impact factor: 16.971

7.  Selection of 2'-Deoxy-2'-Fluoroarabino Nucleic Acid (FANA) Aptamers That Bind HIV-1 Integrase with Picomolar Affinity.

Authors:  Kevin M Rose; Irani Alves Ferreira-Bravo; Min Li; Robert Craigie; Mark A Ditzler; Philipp Holliger; Jeffrey J DeStefano
Journal:  ACS Chem Biol       Date:  2019-10-07       Impact factor: 5.100

8.  Xeno-Nucleic Acid (XNA) 2'-Fluoro-Arabino Nucleic Acid (FANA) Aptamers to the Receptor-Binding Domain of SARS-CoV-2 S Protein Block ACE2 Binding.

Authors:  Irani Alves Ferreira-Bravo; Jeffrey J DeStefano
Journal:  Viruses       Date:  2021-10-02       Impact factor: 5.818

9.  One-step selection of Vaccinia virus-binding DNA aptamers by MonoLEX.

Authors:  Andreas Nitsche; Andreas Kurth; Anna Dunkhorst; Oliver Pänke; Hendrik Sielaff; Wolfgang Junge; Doreen Muth; Frieder Scheller; Walter Stöcklein; Claudia Dahmen; Georg Pauli; Andreas Kage
Journal:  BMC Biotechnol       Date:  2007-08-15       Impact factor: 2.563

Review 10.  Aptasensors for detection of microbial and viral pathogens.

Authors:  Edith Torres-Chavolla; Evangelyn C Alocilja
Journal:  Biosens Bioelectron       Date:  2008-11-25       Impact factor: 10.618

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.